Cathie Wood’s ARK ETF disclosed its daily trades for Monday, April 21st, 2025, showcasing a mix of strategic buys and sells within the biotech sector. Leading the transactions was the sale of 195,933 shares of Adaptive Biotechnologies Corp (NASDAQ:ADPT) from its ARKG ETF, amounting to approximately $1.44 million. This move was the largest in terms of dollar value for the day, indicating a significant adjustment in ARK’s biotech portfolio.
On the buying side, ARK’s ARKG ETF acquired 2161 shares of biopharmaceutical giant Amgen Inc (NASDAQ:AMGN), with a total investment of around $599,223. This purchase signals a growing interest in the established biotech company, known for its innovative treatments and steady market presence.
Continuing its investment in the sector, ARK also purchased 46,183 shares of Beam Therapeutics Inc (NASDAQ:BEAM), a company specializing in precision genetic medicines, totaling $785,111. This acquisition aligns with ARK’s focus on companies at the forefront of scientific advancements.
Further investments included 12,756 shares of Nurix Therapeutics Inc (NASDAQ:NRIX) for $130,621, 19,879 shares of Intellia Therapeutics Inc (NASDAQ:NTLA) for $143,725, and a substantial buy of 143,509 shares of Pacific Biosciences of California Inc (NASDAQ:PACB) for $167,905. The latter, known for its sophisticated gene sequencing technology, has seen consistent interest from ARK, suggesting a bullish outlook on the company’s growth potential.
Additionally, ARK bolstered its position in 10X Genomics Inc (NASDAQ:TXG), a company that develops platforms for analyzing biological systems, by purchasing 86,100 shares valued at $646,611. This follows a pattern of increasing stakes in companies that offer advanced tools for genetic research.
On the sell side, minor transactions included the sale of 33 shares of Prime Medicine Inc (NASDAQ:PRME) through its ARKK ETF for a mere $40, and 47 shares of Repare Therapeutics Inc (NASDAQ:RPTX) through its ARKG ETF for $56. These trades, while minimal in value, reflect ARK’s ongoing portfolio adjustments.
Reviewing the previous week’s activity, ARK exhibited a trend of divesting from certain holdings, including the ARK 21Shares Bitcoin ETF (NYSEARCA:ARKB) and Repare Therapeutics Inc (NASDAQ:RPTX), while showing a pattern of increasing shares in companies such as 3IQ Solana Staking ETF (SOLQ.U) and AeroVironment Inc (NASDAQ:AVAV). These movements highlight ARK’s dynamic investment strategy, constantly adapting to market changes and future growth prospects.
Investors following Cathie Wood’s ARK ETF trades should note the fund’s strategic positioning, as it appears to be shaping its portfolio to capitalize on the next wave of biotechnological innovation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.